Who
Paul Rutherford Carter
Director
Company insider
Files Form 4 as: Director, Immatics; Director, Mallinckrodt; Director, Alder Biopharmaceuticals; EVP Commercial Ops, Gilead Sciences.
In numbers
- Trades disclosed
- 201
- Buys
- 0
- Sells
- 39
- Bought
- $0
- Sold
- $31.3M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 10 Feb 2014
- Last trade
- 16 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 18 Jun 2026 | IMTX Immaticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | IMTX Immaticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | Mallinckrodt | SEC FORM 4 Code D | —20,320 at $0.00 | filing |
| 13 May 2020filed 15 May 2020 | Mallinckrodt | SEC FORM 4 Code F | $27K9,117 at $2.96 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —22,500 at $0.00 | filing |
| 23 May 2019filed 28 May 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 15 May 2019filed 17 May 2019 | Mallinckrodt | SEC FORM 4 Code F | $135K8,906 at $15.21 | filing |
| 15 May 2019filed 17 May 2019 | Mallinckrodt | SEC FORM 4 Code A | —19,396 at $0.00 | filing |
| 23 May 2018filed 25 May 2018 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 16 May 2018filed 18 May 2018 | Mallinckrodt | SEC FORM 4 Code A | —18,947 at $0.00 | filing |
| 24 May 2017filed 26 May 2017 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 1 Aug 2016filed 3 Aug 2016 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | $74K1,817 at $40.56 | filing |
| 1 Aug 2016filed 3 Aug 2016 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | $4,559183 at $24.91 | filing |
| 1 Aug 2016filed 3 Aug 2016 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $160K2,000 at $79.81 | filing |
| 1 Aug 2016filed 3 Aug 2016 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,817 at $0.00 | filing |
| 1 Aug 2016filed 3 Aug 2016 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —183 at $0.00 | filing |
News
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?GILD · fool.com · 18 Oct 2026Gilead Sciences Clears Its February High at $153.54GILD · 247wallst.com · 15 Oct 2026Gilead Sciences, Inc. $GILD Stock Acquired by First Citizens Bank & Trust Co.GILD · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name Paul Rutherford Carter; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.